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Abstract
Cre-loxp mediated conditional knockout strategy has played critical roles for revealing functions of many genes essential for
development, as well as the causal relationships between gene mutations and diseases in the postnatal adult mice. One key
factor of this strategy is the availability of mice with tissue- or cell type-specific Cre expression. However, the success of the
traditional molecular cloning approach to generate mice with tissue specific Cre expression often depends on luck. Here we
provide a better alternative by using bacterial artificial chromosome (BAC)-based recombineering to insert iCreERT2 cDNA at
the ATG start of the Upk2 gene. The BAC-based transgenic mice express the inducible Cre specifically in the urothelium as
demonstrated by mRNA expression and staining for LacZ expression after crossing with a Rosa26 reporter mouse. Taking
into consideration the size of the gene of interest and neighboring genes included in a BAC, this method should be widely
applicable for generation of mice with tissue specific gene expression or deletions in a more specific manner than
previously reported.
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Introduction
Bladder cancer is one of the major causes of malignancy-related
morbidity and mortality worldwide, representing the 7
th most
common type of cancer world wide and the 4
th in developed
countries [1]. More than 90% of bladder cancers correspond to
urothelial carcinomas, since gene mutations are believed to occur
in the urothelium, thus initiating malignant transformation.
Profiling of bladder cancer samples from patients has revealed
frequent inactivation mutations of key tumor suppressor genes
such as PTEN, TP53, and RB [2]. However, the causal relationship
between these mutations and bladder cancer development has not
been well studied in genetic mouse models of bladder cancer due
to the lack of suitable transgenic mice that can be used to
inactivate these tumor suppressors in the adult, since Pten and Rb
are required for embryonic development, and Pten/Rb deficient
mice are not born [3,4].
The Upk2 promoter has been used successfully in driving
expression of Cre [5] and a modified reverse tetracycline trans-
activator[6] in urothelium specific fashion, as well as in the
generation of two transgenic mouse models of invasive and
superficial bladder cancers [7,8]. This breakthrough in bladder
cancer modeling was made possible only after large-scale protein
purification from bovine bladder followed by cloning of the
urothelial specific Uroplakins[9,10]. On view of these published
works, we therefore generated a mouse line that expresses an
inducible CreERT2 recombinase under 3.6 kb of the Upk2
promoter sequence. Surprisingly, we found that CreERT2
expression was not exclusively observed in the urothelium of
bladder and ureters, but also in testis and brain (unpublished
observation), which is in concordance with previous reports that
described the use of the same Upk2 promoter for the generation of
transgenic mice [10,11]. Recently, it was found that there is
sporadic ectopic expression of Cre in tumors developed in the skin
and the lung using the same Upk2 promoter driven Cre mouse,
indicating limitations of tissue specificity conferred by the short
promoter although the unexpected Upk2 promoter activity was
beneficial to the particular study [12].
To overcome this non-specificity, we reasoned that by using a
much large construct such as a bacterial artificial chromosome
(BAC) that contains most, if not all, transcriptional determinants of
a gene, the tissue specific expression would be guaranteed. It is
noteworthy that BAC-based transgenic approach has been used
extensively in the field of neuroscience where complex composi-
tion of cell types in the brain demands absolutely specific transgene
expression [13,14]. Likewise, increasing number of researchers in
other fields has adopted this approach to achieve cell specific gene
expression [15,16,17,18]. As a further demonstration of the
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the mouse genome with a syntenic human BAC DNA, humanized
mice can be made to better modeling human diseases [19].
Indeed, using recombineering [20], we were able to precisely
modify a BAC clone that contains the Upk2 gene to generate a
BAC-based transgenic mouse line with restricted expression of
CreERT2 in the urothelium, which we named as TgUICBAC.
Results and Discussion
Upk2 is a single gene in the mouse genome, and is flanked by
Foxr1 and BCl9l on mouse chromosome 9. Using recombineering,
we inserted a codon-improved iCreERT2 [21] together with a
polyA tail into the ATG of Upk2 translational start site of a BAC
clone that contains the Upk2 gene (Figure 1A). This modified BAC
clone was subsequently injected into fertilized eggs of B6CBA/F1
mice to generate transgenic TgUICBAC mice. Two mice were
identified to contain the transgene based on genotyping by
polymerase chain reaction (PCR) and Southern blot analyses:
Mouse #1 and #5 had 2 and 4 copies of the transgene,
respectively, based on the intensity of signals on the Southern blot
in comparison with that of the endogenous Upk2 allele (Figure 1B).
Only mouse #1 which showed a low copy number of the
transgene was able to produce offspring; therefore, it was used for
further characterization of the TgUICBAC mice. The transgenic
mice showed no phenotypic alterations and bred normally,
producing offspring with regular number of litters.
To confirm that iCreERT2 expression was specific to the
urothelium, total RNA was extracted from the major organs of
male and female transgenic mice and subjected to RT-PCR
analysis using specific primers to iCreERT2. Indeed, differently to
previously reported Upk2-based transgenic mice [10,11] and our
TgUPCreERT2 mice (unpublished observation), only organs that
contain urothelium express the transgene, such as bladder, ureter,
and kidney (renal pelvis), whereas no other organs such as brain
and testis were found to express the transgene (Figure 2). To
further prove the specificity and in vivo activity of iCreERT2,
TgUICBAC mice were crossed with Rosa26 reporter mice in which
a floxed stop cassette is placed before the LacZ gene so that LacZ
expression is allowed only after the stop cassette removal mediated
by Cre activity [22]. When the compound mice were administered
Tamoxifen by injection, X-gal staining revealed a strong and
distinct blue staining in the epithelial cells of the urothelium of
bladder, whereas no blue staining was observed in bladder tissue of
control mice which received only oil injection (Figure 3A). To
assess the percentage of recombination, we performed double
immunofluorescence using antibodies against Upk2 and b-
galactosidase (Figure 3B), and quantified co-expression of these
two markers (Figure 3C). This analysis revealed that recombina-
tion rate was observed in most of the Upk2 expressing cells
(82.3%6 11.2%) in the four representative mice analyzed,
underlining the potential use of our model. No significant
differences were observed between female and male bladder
recombination rates, which corresponded to 85.8%6 10.9% and
78.7%6 11.3%, respectively (p=0.297). As further evidence of
the Cre specificity, X-gal staining was also found in the urothelium
of ureter, and renal pelvis, but not in other organs that do not
Figure 1. Generation of mice carrying insertion of iCreERT2 into the ATG of Upk2 gene. A) The BAC clone bMQ-343M5 contains the Upk2
gene flanked by parts of Foxr1 and Blr1 genes, which together with Upk2 gene are all transcribed from reverse strand, and Bcl9l, which is from forward
strand. The size of the BAC clone insert is 82951 bp (from 44267673 to 44184722 in mouse chromosome 9). iCreERT2-pA is inserted into the ATG start
of Upk2 gene. ScaI sites and probes for southern blot (P5) are shown. Arrows indicate primers used for PCR genotyping. B) Mouse genotyping by PCR
(upper panel) and Southern blot (lower panel). Positive founder lines (#1 and #5) are marked with circles. UIC stands for the TgUICBAC transgene.
doi:10.1371/journal.pone.0035243.g001
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indicate that we have generated an urothelium-specific and
tamoxifen-inducible Cre mouse line with a high recombination
rate in the urothelium of both male and female.
Because the BAC clone that was used for this study included
genes flanking Upk2, namely Bcl9l, Blr1 (or Cxcr5) and Foxr1, and
the transgenic founder with higher copy number of the BAC was
unable to breed (Figure 1), overexpression of these genes may have
phenotypic consequences. Therefore, we performed quantitative
RT-PCR to determine the transcript levels of such genes in the
bladder of TgUICBAC mice that breed normally with low copy
number of the BAC. As expected, the transcript levels of these
three genes are significantly up-regulated in the bladder of the
transgenic mice compared to those in wild type mice (Figure S1).
Although there are no phenotypic changes in the established
TgUICBAC mouse line, it is necessary to identify and separate
potential effects of overexpression of the three genes on the
phenotypes of interest by including proper control groups, as it is
usually the case in studies of mouse modeling of human diseases.
The specificity of the TgUICBAC transgene expression confirms
that Upk2 is an urothelium marker [23], suggesting that the short
Upk2 promoter may lack some transcriptional determinants to
allow transgene expression non-specifically in other organs such as
brain and testis. This mouse line that we have generated will be a
critical tool for conditional inactivation of tumor suppressors
specifically in the urothelium for bladder cancer modeling.
Recombineering is a homologous recombination mediated
genetic engineering in bacteria [20]. It does not rely on the
presence (or absence) of restriction sites that traditional molecular
cloning requires. It has the capability to modify at nucleotide level
precision any possible genetic modifications on a large DNA
molecule, such as a BAC clone. Because of its size at the average of
over 100 kb [24], a BAC clone usually covers the entire genomic
structures of most genes in the mouse genome, it is perhaps not
surprising that a BAC-based transgenic mouse approach as
described here will provide faithful gene expression and will be
the future trend in the generation of transgenic mice for various
purposes.
Figure 2. iCreERT2 expression in TgUICBAC mice. Total RNA from various organs of male (M) and female (F) mice were extracted, and subjected
to RT-PCR analysis of iCreERT2 expression. Note that iCreERT2 expression is observed only in kidney (renal pelvis), ureter and bladder, revealing that it
is specific of organs coated with urothelium. Mouse Gapdh served as a control.
doi:10.1371/journal.pone.0035243.g002
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PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e35243Figure 3. iCreERT2 activity in TgUICBAC mice in vivo. A) Eight week old TgUICBAC;Rosa26 mice were injected with Tamoxifen for 3 days (TAM)
or equal volume of sunflower oil (OIL, control group). Mice were sacrificed one week after injection, bladder sections were obtained and X-gal
staining was performed. Note that X-gal blue staining is observed in the epithelial cells of the bladder in mice injected with TAM, whereas no staining
is observed in the bladder of control mice. Bars correspond to 100 mm. B) Representative immunofluorescence analysis of Upk2 (green) and ß-
galactosidase (red) co-expression in bladder urothelium of TgUICBAC;Rosa26 mice injected with Tamoxifen. Note that most of the Upk2-positive
urothelial cells show a doted staining for ß-galactosidase. Bars correspond to 100 mm. C) Quantification of percentage of recombination in the
analyzed bladder sections from 2 female and 2 male transgenic mice illustrated by mean 6 SD.
doi:10.1371/journal.pone.0035243.g003
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PLoS ONE | www.plosone.org 4 April 2012 | Volume 7 | Issue 4 | e35243Figure 4. Tissue-specific activity of iCReERT2 in vivo. Eight week old TgUICBAC;Rosa26 mice were treated as in Figure 3, sections of other
organs were obtained and X-gal staining was performed. Note that X-gal blue staining is observed only in the epithelial cells of the renal pelvis, ureter
(indicated with arrows) in mice injected with TAM, whereas no staining is observed in control mice or other organs of TAM-injected mice. Bars
correspond to 100 mm.
doi:10.1371/journal.pone.0035243.g004
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in the BAC as identified in this work represents a common but
often neglected issue in the BAC-based transgenic organisms,
which is usually the case when the size of the gene of interest is
small. Neighboring genes in a BAC can be removed by
recombineering provided that these genetic elements do not
contribute to the specificity of expression of the gene of interest.
On the other hand, if a gene is too big (such as over 200 kb), the
BAC-based transgenic approach is not reliable because of the size
limitations of average BACs. If these are major concerns in both
scenarios, a targeted knock-in will be the best choice. In spite of
these shortcomings, the BAC-based transgenic approach is faster
and easier than gene targeting, and even advantageous when
adding an extra-targeted allele is less desirable than a simple
transgene in the complicated breeding scheme to get multiple
targeted genes in a single mouse.
Methods
Ethic Statement
All procedures involving mice were conducted in accordance
with National Institutes of Health regulations concerning the use
and care of experimental animals, and according to the
approved animal use and care protocol (AAAA7254) at the
Herbert Irving Comprehensive Cancer Center of Columbia
University.
Mouse Strains
Rosa26 reporter mice [22] and C57BL/6 mice were
purchased from Jackson Laboratory. The TgUICBAC founder
mice were in a B6CBA/F1 background, and founder line #1
was backcrossed with C57BL/6 for more than 10 generations.
The established TgUICBAC mice have normal appearance and
behavior.
BAC Transgene Construction
A mouse BAC clone with the Upk2 gene in the middle and
flanked by large genomic regions at either side was obtained
from an annotated 129Sv BAC library [24]. The BAC DNA
was purified using a regular plasmid DNA mini-prep kit
(Qiagen, Valencia, CA) and was used as a template to verify
the content by PCR using primers that amplify a segment of
Upk2 gene. The PCR product was sequenced and confirmed.
The iCreERT2 cDNA and a polyA tail together with a flrted
selection marker Amp coding for resistance to Ampicillin was
amplified using high fidelity DNA polymerase (New England
Biolabs, Ipswich, MA). Primers were 100 nt long and allowed
the amplification of the iCreERT2 cassette flanked by sequences
at both sides of the ATG start site of the Upk2 gene. The
primers were synthesized by Invitrogen (Invitrogen, Carlsbad,
CA). The PCR product was purified and completely sequenced
to verify that there were no un-intended mutations. Then
100 ng of the purified PCR product and 10 ng of the BAC
DNA were co-electroporated into 105 competent cells that are
capable of recombineering [25]. After Chloramphenicol and
Ampicillin selection, the survived clones were picked and
verified by PCR and sequencing of the PCR product to verify
the location of the insertion. Restriction digestion with SpeI was
performed to confirm that there was no re-arrangement of the
modified BAC clone compared to its parental clone. Then the
Table 1. Primer sequences for generation and characterization of TgUICBAC mice.
Primers (59R39) and Applications
ATTGGCCCCAGGAAACCCCAGCCTGTCAGCACCTGTTCCAGGATCCAGTTCCCAGCGCAGTATGgatatctccaacctgctg (forward)
GAGCCAGGACAGCCAGCAGAATCAGGATCAGGGGCAAGGTCTGGACAGGCAGTGTGGATGCgctagccgttaattaagaag (reverse)
Using pIndu-perfect as a template to get a 3498 bp iCreERT2 Cassette. Capital letters are from Upk2 sequence, lower-case letters are from iCreERT2 sequence.
CTGAGGCTACAGTGCCCAAG (forward)
GTCTAGCGCTCTGAAACCCTC (reverse)
Using modified BAC DNA as a template to get a 3772 bp (or 274 bp for unmodified BAC) product.
cttatcgatgataagctgtcaaacatgagaattgatccggaacccttaatTCTTAGACGTCAGGTGGCAC (forward)
ccgatgcaagtgtgtcgctgtcgacggtgaccctatagtcgagggacctaTCACGTTAAGGGATTTTGGT (reverse)
Using pTAMP as a template to get a 860 bp Amp cassette to delete the loxp site in BACe3.6. Lower-case letters are from BAC3.6 sequence, capital letters are from Amp
sequence.
ATGGATATCTCCAACCTGCTG (forward)
AGATCTCCTGTGCAGCATG (reverse)
Using tail genomic DNA to get a 312 bp product for TgUICBAC transgenic mice PCR genotyping.
TGCTCCCAGGTGGTGGATCTC (forward)
CTCAAAGCGGACCTCCTGTTC (reverse)
Using BAC DNA as a template to get a 389 bp probe for Southern blot genotyping. Using the probe and ScaI digestion to get 8869 bp and 11196 bp for transgenic and
Wt allele on Sothern blot, respectively.
CGCGAGAGGAGTGTGTCTG (forward)
CTCTGAATCGAGGGATGGAGT (reverse)
qRT-PCR for Bcl9l
AGGCCGAGCAGAAACTTGC (forward)
GGCTTAATGTCTGGACCATCTTT (reverse)
qRT-PCR for Foxr1
TGGCCTTCTACAGTAACAGCA (forward)
GCATGAATACCGCCTTAAAGGAC (reverse)
qRT-PCR for Cxcr5
AGGTCGGTGTGAACGGATTTG (forward)
GGGGTCGTTGATGGCAACA (reverse)
qRT-PCR for Gapdh
doi:10.1371/journal.pone.0035243.t001
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Finally, the loxp site present in the BAC clone was deleted by
recombineering using Amp as a selection marker. The final BAC
DNA was purified using a large construct purification kit
(Clontech, Mountain View, CA), and subject to microinjection
into fertilized eggs of B6CBA/F1 mice at the transgenic core
facility of the Herbert Irving Comprehensive Cancer Center of
Columbia University. Primers used in these procedures are
summarized in Table 1.
Mouse Genotyping
A mix of three primers was used to genotype Rosa26 reporter
mice as previously described [22]. The genotyping of TgUIC-
BAC mice was done by PCR using primers that amplified a
segment of iCreERT2, and by Southern blot using a probe
outside of the Upk2 gene to identify both the endogenous allele
and the transgene. PCR was performed at the following
conditions using HotStarTaq Master Mix (Qiagen, Valencia,
CA): 95uC for 159, 30 cycles of 95uC for 300,5 7 uC for 19,7 2 uC
for 19 and 72uC for 59 for the last cycle yielding a 312-bp
product for the transgenic allele. Southern Blot was performed
following standard procedures. Briefly, mouse tail genomic DNA
was extracted using proteinase K digestion and ethanol
precipitation. After ScaI digestion, the DNA fragments were
resolved by agarose gel electrophoresis, transferred to a hybond
membrane (GE Healthcare, Piscataway, NJ), and hybridized
with the
32P-labeled 389-bp DNA probe located upstream of
the mouse Upk2 promoter. After autoradiography, the copy
number of the transgene was determined by comparing the
relative density of the transgene with that of the endogenous
Upk2 gene. PCR was used for routine genotyping for the
following generations of transgenic mice. Primers and probes
used in these procedures are summarized in Table 1.
RT-PCR and qRT-PCR Analyses
Total RNA was isolated from major organs of TgUICBAC
mice (both sexes) by QIAzol (Qiagen) according to the
manufacturer’s instructions. The RNA integrity was verified
by electrophoresis on a 1.2% agarose gel and was visualized
with ethidium bromide staining. The concentration was
quantified by ultraviolet absorption with a NanoDrop spectro-
photometer (Thermo Scientific). One mg of total RNA from
each sample was subjected to first-strand cDNA synthesis using
SuperScript
TMIII First-Strand Synthesis System for RT-PCR
(Invitrogen). RT-PCR was carried out using the GeneAmp PCR
System 9700 (Applied Biosystems). Two ml of obtained cDNA
were used as template for amplification of a fragment of the
iCreERT2. Gapdh was used as a control[26]. PCR was
performed at the following conditions using HotStarTaq Master
Mix (Qiagen): 95uC for 159, 30 cycles of 95uC for 300,5 7 uC for
19,7 2 uC for 19 and 72uC for 59 for the last cycle. PCR
products were analyzed on 2% agarose gels.
qRT-PCR was conducted using the Mastercycler epgradient
S realplex
4 (Eppendorf) in accordance to the manufacturer’s
instructions. RNA transcript levels of Foxr1, Bcl9l and Cxcr5
from 6 TgUICBAC bladders (3 females and 3 males) were
compared to 6 wild type bladders (3 females and 3 males).
qRT-PCR contained in a final volume of 20 ml, 10 mlo f2 x
QuantiTect SYBR Green PCR Master Mix (Qiagen), 1 mlo f
cDNA, and 2 ml of the forward and reverse primers. The
thermal cycling conditions were: 95uC for 159, and 40 cycles of
94uC for 300,5 6 uC for 400 and 72uC for 300. The PCR
products were analyzed by melting curve analysis and agarose
gel electrophoresis to confirm that no by-products were formed.
The relative concentrations of the PCR products derived from
the target gene were calculated using the realplex software
(Eppendorf) using the DDCT method [27]. The results were
expressed relative to the levels of a housekeeping gene Gapdh.
All experiments were conducted in triplicate. Primers used in
these procedures are summarized in Table 1.
LacZ Staining
TgUICBAC mice were crossed with Rosa26 reporter mice and
the compound mice were subjected to administration of
Tamoxifen (Sigma-Aldrich, i.p., 0.15 mg/g body weight, in
15mg/ml of sun flower oil, for 3 consecutive days) or of equal
volume of sun flower oil (control group). One week after the last
injection, mice were euthanized, major organs were taken out
and embedded in OCT. X-gal staining was performed following
standard protocol. Briefly, frozen 10 mm sections were fixed
with 4% paraformaldehyde in PBS (pH=7.4) for 10 minutes at
4uC. Then sections were stained with 1mg/ml X-gal in PBS
(pH=7.4) containing 5mM K4Fe(CN)6, 5mM K3Fe(CN)6, 2mM
MgCl2, 0.1% NP-40, and 0.1% sodium deoxycholate at 37uC
for 15 hours. After being washed in PBS, sections were fixed
with 10% formalin for 10 minutes, counterstained with nuclear
fast red for 5 minutes and mounted with an aqueous mounting
medium.
Immunofluorescence Analysis and Recombination
Quantification
Double immunofluorescence analysis was performed on 10-mm
frozen tissue sections from four Tamoxifen injected mouse bladder
samples (2 females and 2 males) to determine the rate of co-
expression of Upk2 and ß-galactosidase. Sections were fixed for
10 minutes with 4% Paraformaldehyde and after washing in 1X
PBS submitted to antigen retrieval by steam treatment for
15 minutes in 10 mM citrate buffer, pH 6.0. Slides were then
treated with 10% normal horse serum for 30 minutes, followed by
ß-galactosidase antibody (mouse monoclonal 40–1a, Santa Cruz)
incubation overnight at 4uC. Slides were then incubated with
biotinylated secondary antibodies (Vector Laboratories) for
30 minutes, followed by strepatvidin-594 (Invitrogen) incubation
for 60 minutes. After that, slides were blocked with 10% normal
donkey serum for 30 minutes, followed by Upk2 antibody (goat
polyclonal, Santa Cruz) incubation overnight at 4uC. Slides were
then incubated with Alexa FluorH 488 IgG secondary antibodies
(Invitrogen) for 60 minutes and then mounted with Vectashileld
mounting medium containing DAPI (Vector Laboratories). The
antibodies against Upk2 and ß-galactosidase were specific, because
urothelial staining was absent when they were omitted as the first
antibodies.
For quantification of recombination, we determined the
percentage of expression of b-galactosidase in Upk2-expressing
cells identified in 5 microscopic high power fields (HPF) of each
bladder section. Specifically, in each of the 4 bladder samples
analyzed, random areas containing urothelium were identified by
DAPI staining at low magnification, and then 5 HPF were
analyzed by counting the number of cells displaying a Upk2-
positive phenotype and then counting the cells with b-galactosi-
dase positivity. Average of recombination was assessed for the 2
female and 2 male samples separately.
Statistical Analysis
Statistical analysis was done with IBM SPSS Statistics v19.0.
t-test was used to assess differences in transcript expression of
Foxr1, Bcl9l and Cxcr5 genes between bladders of wild type and
TgUICBAC mice, and to assess differences of co-expression of
Inducible Cre in the Urothelium
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urothelium. All statistical tests were 2-sided with significance
considered at p=0.05.
Supporting Information
Figure S1 qRT-PCR analysis of relative expression
levels of Bcl9l, Cxcr5, and Foxr1 in the bladders of Wt
(set to 1) and TgUICBAC mice. Mouse Gapdh expression level
was used as control. Refer to ‘‘Method’’ for more detail. In a brief
summary, Bcl9l showed a 2.2-fold increase in male (p=0.014) and
1.8-fold increase in female (p=0.02); Cxcr5 showed a 20.8-fold
increase in male (p=0.013) and 21.7-fold increase in female
(p=0.002); and Foxr1 showed a 40.0-fold increase in male
(p=0.033) and 43.0-fold increase in female (p=0.006). No
significant differences were observed between male and female
TgUICBAC mice in transcript levels of the three genes.
(TIF)
Acknowledgments
We would like to thank Gu ¨nther Schu ¨tz (German Cancer Research
Center) for sharing reagents for this project; Chyuan-Sheng Lin (Herbert
Irving Comprehensive Cancer Center of Columbia University) for
pronuclear DNA injection.
Author Contributions
Conceived and designed the experiments: THS NG MCM CCC.
Performed the experiments: THS NG MCM DB JDD DC. Analyzed
the data: THS NG MCM DB JDD DC CCC. Contributed reagents/
materials/analysis tools: THS NG MCM CCC. Wrote the paper: THS
NG MCM CCC.
References
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer
statistics. CA Cancer J Clin 61: 69–90.
2. Cordon-Cardo C (2008) Molecular alterations associated with bladder cancer
initiation and progression. Scand J Urol Nephrol Suppl. pp 154–165.
3. Marino S, Vooijs M, van Der Gulden H, Jonkers J, Berns A (2000) Induction of
medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the
external granular layer cells of the cerebellum. Genes Dev 14: 994–1004.
4. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP (1998) Pten is essential
for embryonic development and tumour suppression. Nat Genet 19: 348–355.
5. Mo L, Cheng J, Lee EY, Sun TT, Wu XR (2005) Gene deletion in urothelium
by specific expression of Cre recombinase. Am J Physiol Renal Physiol 289:
F562–568.
6. Zhou H, Liu Y, He F, Mo L, Sun TT, et al. (2010) Temporally and spatially
controllable gene expression and knockout in mouse urothelium. Am J Physiol
Renal Physiol 299: F387–395.
7. Zhang ZT, Pak J, Shapiro E, Sun TT, Wu XR (1999) Urothelium-specific
expression of an oncogene in transgenic mice induced the formation of
carcinoma in situ and invasive transitional cell carcinoma. Cancer Res 59:
3512–3517.
8. Zhang ZT, Pak J, Huang HY, Shapiro E, Sun TT, et al. (2001) Role of Ha-ras
activation in superficial papillary pathway of urothelial tumor formation.
Oncogene 20: 1973–1980.
9. Wu XR, Manabe M, Yu J, Sun TT (1990) Large scale purification and
immunolocalization of bovine uroplakins I, II, and III. Molecular markers of
urothelial differentiation. J Biol Chem 265: 19170–19179.
10. Lin JH, Zhao H, Sun TT (1995) A tissue-specific promoter that can drive a
foreign gene to express in the suprabasal urothelial cells of transgenic mice. Proc
Natl Acad Sci U S A 92: 679–683.
11. Kerr DE, Liang F, Bondioli KR, Zhao H, Kreibich G, et al. (1998) The bladder
as a bioreactor: urothelium production and secretion of growth hormone into
urine. Nat Biotechnol 16: 75–79.
12. Ahmad I, Singh LB, Foth M, Morris CA, Taketo MM, et al. (2011) K-Ras and
beta-catenin mutations cooperate with Fgfr3 mutations in mice to promote
tumorigenesis in the skin and lung, but not in the bladder. Dis Model Mech 4:
548–555.
13. Heiman M, Schaefer A, Gong S, Peterson JD, Day M, et al. (2008) A
translational profiling approach for the molecular characterization of CNS cell
types. Cell 135: 738–748.
14. Zhao S, Ting JT, Atallah HE, Qiu L, Tan J, et al. (2011) Cell type-specific
channelrhodopsin-2 transgenic mice for optogenetic dissection of neural
circuitry function. Nat Methods 8: 745–752.
15. Yang XD, Ai W, Asfaha S, Bhagat G, Friedman RA, et al. (2011) Histamine
deficiency promotes inflammation-associated carcinogenesis through reduced
myeloid maturation and accumulation of CD11b+Ly6G+ immature myeloid
cells. Nat Med 17: 87–95.
16. Wrann CD, Eguchi J, Bozec A, Xu Z, Mikkelsen T, et al. (2012) FOSL2
promotes leptin gene expression in human and mouse adipocytes. J Clin Invest
122: 1010–1021.
17. Miloud T, Fiegler N, Suffner J, Hammerling GJ, Garbi N (2012) Organ-specific
cellular requirements for in vivo dendritic cell generation. J Immunol 188:
1125–1135.
18. Blondeau B, Sahly I, Massourides E, Singh-Estivalet A, Valtat B, et al. (2012)
Novel transgenic mice for inducible gene overexpression in pancreatic cells
define glucocorticoid receptor-mediated regulations of Beta cells. PLoS One 7:
e30210.
19. Wallace HA, Marques-Kranc F, Richardson M, Luna-Crespo F, Sharpe JA, et
al. (2007) Manipulating the mouse genome to engineer precise functional
syntenic replacements with human sequence. Cell 128: 197–209.
20. Copeland NG, Jenkins NA, Court DL (2001) Recombineering: a powerful new
tool for mouse functional genomics. Nat Rev Genet 2: 769–779.
21. Erdmann G, Schutz G, Berger S (2007) Inducible gene inactivation in neurons
of the adult mouse forebrain. BMC Neurosci 8: 63.
22. Soriano P (1999) Generalized lacZ expression with the ROSA26 Cre reporter
strain. Nat Genet 21: 70–71.
23. Wu XR, Kong XP, Pellicer A, Kreibich G, Sun TT (2009) Uroplakins in
urothelial biology, function, and disease. Kidney Int 75: 1153–1165.
24. Adams DJ, Quail MA, Cox T, van der Weyden L, Gorick BD, et al. (2005) A
genome-wide, end-sequenced 129Sv BAC library resource for targeting vector
construction. Genomics 86: 753–758.
25. Warming S, Costantino N, Court DL, Jenkins NA, Copeland NG (2005) Simple
and highly efficient BAC recombineering using galK selection. Nucleic Acids
Res 33: e36.
26. Kim JE, Nakashima K, de Crombrugghe B (2004) Transgenic mice expressing a
ligand-inducible cre recombinase in osteoblasts and odontoblasts: a new tool to
examine physiology and disease of postnatal bone and tooth. Am J Pathol 165:
1875–1882.
27. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using
real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:
402–408.
Inducible Cre in the Urothelium
PLoS ONE | www.plosone.org 8 April 2012 | Volume 7 | Issue 4 | e35243